Research Roundup

Debbie Rigby takes a look at the latest in research news

Management of insomnia in primary care

Insomnia is a common sleep disorder involving difficulty initiating or maintaining sleep and results in daytime consequences. A short course of an hypnotic medicine may be appropriate for acute insomnia; however, cognitive behavioural therapy for insomnia is recommended for management of acute and chronic insomnia. Melatonin may be useful in patients with a circadian rhythm disturbance, resulting in sleep onset insomnia or early morning awakening. Suvorexant can be an effective treatment in sleep maintenance insomnia due to hyperarousal.

Aust Prescr 2021;44:124-28.

Ocular adverse effects of oral drugs

Some commonly prescribed drugs have ocular adverse effects. These include alpha1-adrenergic receptor antagonists, antiarrhythmics, digoxin, allopurinol, anticholinergics, anticoagulants, antiepileptics, gabapentin, bisphosphonates, corticosteroids, tamoxifen, tetracyclines and many others.

Aust Prescr 2021;44:129-36

Single-inhaler triple vs single-inhaler dual therapy in patients with COPD

A meta-analysis of RCTs has concluded that single-inhaler triple therapy is effective in reducing the risk of death of any cause and of moderate or severe exacerbation in patients with COPD. However, the risk of pneumonia is 55% higher with single inhaler triple therapy than with single inhaler dual bronchodilator therapy.

Respiratory Research 2021;22:209.

Association between ICS use and risk of hyperglycemia in patients with COPD

A systematic review and meta-analysis of 17 RCTs (n=43,430) has concluded that inhaled corticosteroids do not have an effect on the blood glucose and is not associated with the risk of new onset diabetes mellitus and diabetes progression in patients with COPD. The systemic bio-availability of ICS is considered to be minimal.

Respiratory Research 2021;22:201.

Previous ‘Crisis point’ as Guild, PPA talk Award
Next Australia ‘vulnerable’ to meds shortages

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.

No Comment

Leave a reply